CSF parameters are extensively evaluated as biomarkers of neurological disorders in adult patients. Circulating microRNAs in CSF are a promising class of biomarkers for the diagnosis of various neurological diseases. Neurological disorders such as Parkinson’s Disease (PD), Alzheimer’s Disease (AD), epilepsy, and seizures often lead to altered CSF parameters. According to an article published in Nature, 76 CSF proteins were found to be structurally altered in patients that were diagnosed with PD when compared to normal individuals. The study also suggests that these CSF proteins can be used as biomarkers for the diagnosis or treatment of the disease. PD is a neurodegenerative disease associated with loss of cognitive impairment and motor function. According to the World Health Organization (WHO) report published in 2022, the prevalence of PD has doubled in the last 25 years, affecting ~1% of the global population aged more than 60 years. Similarly, a few of the CSF parameters such as protein and lactate levels are altered in patients suffering from seizure or status epilepticus. Therefore, various R&D activities are going on for using CSF parameters in the treatment of seizures or epilepsy. Further, despite the availability of various CSF assays for the detection of Alzheimer’s disease using CSF in the market, there are unmet needs for biomarkers for detection and treatment purposes. As the detection of cases of Alzheimer’s disease and PD increases, there is increase in demand for CSF management devices as the cases of CSF leaks may increases. Therefore, a rise in the prevalence of neurological disorders is fueling the research and development activities for the use of CSF management products in the treatment of these disorders.
The Asia Pacific cerebrospinal fluid management is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Asia Pacific is the fastest-growing market for cerebrospinal fluid management in global scenario. The cerebrospinal fluid management market growth in this region is attributed to growing geriatric population, demand for advanced medical devices, and increasing healthcare infrastructures offering efficient treatments.
The Asia Pacific cerebrospinal fluid management market is segmented into product, end user and country.
Based on product, the Asia Pacific cerebrospinal fluid management market is bifurcated into CSF shunts and CSF drainage systems. The CSF shunts segment held a larger market share in 2022.
Based on end user, the Asia Pacific cerebrospinal fluid management market is segmented into hospitals, clinics, ambulatory surgical centers, and others. The hospitals segment held the largest market share in 2022.
Based on country, the Asia Pacific cerebrospinal fluid management market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific cerebrospinal fluid management market share in 2022.
B. Braun SE, Integra LifeSciences Holdings Corp, Medtronic Plc, Natus Medical Inc, and Spiegelberg GmbH & Co KG are some of the leading companies operating in the Asia Pacific cerebrospinal fluid management market.
The Asia Pacific Cerebrospinal Fluid Management Market is valued at US$ 389.53 Million in 2022, it is projected to reach US$ 613.54 Million by 2030.
As per our report Asia Pacific Cerebrospinal Fluid Management Market, the market size is valued at US$ 389.53 Million in 2022, projecting it to reach US$ 613.54 Million by 2030. This translates to a CAGR of approximately 5.8% during the forecast period.
The Asia Pacific Cerebrospinal Fluid Management Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Cerebrospinal Fluid Management Market report:
The Asia Pacific Cerebrospinal Fluid Management Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific Cerebrospinal Fluid Management Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific Cerebrospinal Fluid Management Market value chain can benefit from the information contained in a comprehensive market report.